Submaximal PPARΥ activation and endothelial dysfunction: New perspectives for the management of cardiovascular disorders

British Journal of Pharmacology

Volumn 166, Issue 7, 2012, Pages 1981-1992

  Balakumar, Pitchai ^a   Kathuria, Sonam ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

EDRF; endothelial function; eNOS; PPAR partial submaximal activation; vascular complications

Indexed keywords

ADIPONECTIN; ARHALOFENATE; ATORVASTATIN; BALAGLITAZONE; CIGLITAZONE; CURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KR 62776; MESSENGER RNA; MEVINOLIN; MK 0533; NITRIC OXIDE; PAM 1616; PAR 1622; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RHO KINASE; ROSIGLITAZONE; ROSUVASTATIN; TELMISARTAN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL PROTECTION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ESSENTIAL HYPERTENSION; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIA; KIDNEY DISEASE; MOLECULAR INTERACTION; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RED WINE; REVIEW; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PPAR GAMMA;

EID: 84863696819     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01938.x     Document Type: Review

References (100)

1. Acton JJ 3rd, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, et al,. (2009). Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6- (trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem 52: 3846-3854.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Balakumar P, Babbar L, (2012). Preconditioning the hyperlipidemic myocardium: fact or fantasy? Cell Signal 24: 589-595.
4. Balakumar P, Kaur J, (2009). Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? Pharmacol Res 60: 361-368.
5. Balakumar P, Mahadevan N, (2012). Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol 165: 373-379.
6. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M, (2007a). PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 56: 91-98.
7. Balakumar P, Rose M, Singh M, (2007b). PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80: 1-10.
8. Balakumar P, Kaur T, Singh M, (2008a). Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 245: 49-64.
9. Balakumar P, Sharma R, Singh M, (2008b). Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol Res 58: 356-363.
10. Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N, (2012). Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol 52: 83-92.
11. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al,. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002.
12. Bernátová I, Pechánová O, Babál P, Kyselá S, Stvrtina S, Andriantsitohaina R, (2002). Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol Heart Circ Physiol 282: H942-H948.
13. Bishop-Bailey D, (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129: 823-834.
14. Blanquicett C, Kang BY, Ritzenthaler JD, Jones DP, Hart CM, (2010). Oxidative stress modulates PPAR gamma in vascular endothelial cells. Free Radic Biol Med 48: 1618-1625.
15. Budzyn K, Marley PD, Sobey CG, (2006). Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27: 97-104.
16. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM, (2003). Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57.
17. Caramori PR, Zago AJ, (2000). Endothelial dysfunction and coronary artery disease. Arq Bras Cardiol 75: 163-182.
18. Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, et al,. (2008). A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur J Pharmacol 584: 192-201.
19. Chen Z, Peng IC, Sun W, Su MI, Hsu PH, Fu Y, et al,. (2009). AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104: 496-505.
20. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al,. (1999). AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443: 285-289.
21. Cho DH, Choi YJ, Jo SA, Jo I, (2004). Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 279: 2499-2506.
22. Cicha I, Urschel K, Daniel WG, Garlichs CD, (2011). Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-α. Clin Hemorheol Microcirc 48: 65-73.
23. Desjardins F, Balligand JL, (2006). Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg 61: 326-334.
24. Desjardins F, Sekkali B, Verreth W, Pelat M, De Keyzer D, Mertens A, et al,. (2008). Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 29: 128-137.
25. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL, (2004). PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36: 295-304.
26. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM, (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
27. Duan SZ, Usher MG, Mortensen RM, (2008). Peroxisome proliferator- activated receptor-gamma-mediated effects in the vasculature. Circ Res 102: 283-294.
28. Dubois M, Vantyghem MC, Schoonjans K, Pattou F, (2002). Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma). Ann Endocrinol (Paris) 63: 511-523.
29. Ferdinandy P, Schulz R, (2003). Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543.
30. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R, (2001). Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-E75.
31. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, et al,. (2002). Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 90: 866-873.
32. Forst T, Hanefeld M, Pfützner A, (2011). Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharmacother 12: 1571-1584.
33. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papap etropoulos A, et al,. (1998). Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 821-824.
34. Govers R, Rabelink TJ, (2001). Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 280: F193-F206.
35. Gratton JP, Fontana J, O'Connor DS, Garcia-Cardena G, McCabe TJ, Sessa WC, (2000). Reconstitution of an endothelial nitric oxide synthase, hsp90 and caveolin-1 complex in vitro: evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J Biol Chem 275: 22268-22272.
36. Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, et al,. (2009). MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol 23: 975-988.
37. Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, et al,. (2011). BALLET Trial Investigators. Efficacy and safety of the PPARΥ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 27: 392-401.
38. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M, (1995). Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 76: 958-962.
39. Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y, Nagai R, (2008). Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 62: 46-52.
40. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, Hart CM, (2005). Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288: C899-C905.
41. Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, et al,. (2008). Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens 26: 964-972.
42. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, et al,. (2006). Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72: 184-190.
43. Jacob A, Wu R, Zhou M, Wang P, (2007). Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res 2007: 89369.
44. Jindal S, Singh M, Balakumar P, (2008). Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol 128: 383-391.
45. Ju H, Zou R, Venema VJ, Venema RC, (1997). Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 272: 18522-18525.
46. Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K, (2011). Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome. Can J Physiol Pharmacol 89: 355-364.
47. Kaur J, Reddy K, Balakumar P, (2010a). The novel role of fenofibrate in preventing nicotine and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovasc Toxicol 10: 227-238.
48. Kaur T, Goel RK, Balakumar P, (2010b). Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Arch Pharmacal Res 33: 611-618.
49. Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, et al,. (2009a). PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Arch Pharm Res 32: 721-727.
50. Kim J, Han DC, Kim JM, Lee SY, Kim SJ, Woo JR, et al,. (2009b). PPAR gamma partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK. Cell Mol Life Sci 66: 1766-1781.
51. Kim MK, Chae YN, Choi SH, Moon HS, Son MH, Bae MH, et al,. (2011). PAM-1616, a selective peroxisome proliferator-activated receptor Υ modulator with preserved anti-diabetic efficacy and reduced adverse effects. Eur J Pharmacol 650: 673-681.
52. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, et al,. (2008). Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 21: 576-581.
53. Kocsis GF, Pipis J, Fekete V, Kovács-Simon A, Odendaal L, Molnár E, et al,. (2008). Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 294: H2406-H2409.
54. Kota BP, Huang TH, Roufogalis BD, (2005). An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85-94.
55. Kroll J, Waltenberger J, (1998). VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252: 743-746.
56. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al,. (2000). Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101: 676-681.
57. Laufs U, La Fata V, Plutzky J, Liao JK, (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135.
58. Lebovitz HE, Banerji MA, (2001). Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56: 265-294.
59. Li R, Zhang H, Wang W, Wang X, Huang Y, Huang C, et al,. (2010). Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling. Eur J Pharmacol 628: 140-147.
60. Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, et al,. (2009). Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 158: 1865-1873.
61. Michel JB, Feron O, Sacks D, Michel T, (1997). Reciprocal regulation of endothelial nitric-oxide synthase by Ca21-calmodulin and caveolin. J Biol Chem 272: 15583-15586.
62. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, et al,. (1999). The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 9: 845-848.
63. Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA, et al,. (2001). Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276: 17625-17628.
64. Miriyala S, Panchatcharam M, Rengarajulu P, (2007). Cardioprotective effects of curcumin. Adv Exp Med Biol 595: 359-377.
65. Mount PF, Kemp BE, Power DA, (2007). Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271-279.
66. Nakagami H, Osako MK, Takami Y, Hanayama R, Koriyama H, Mori M, et al,. (2008). Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice. Mol Med Report 1: 657-661.
67. Naseem KM, (2005). The role of nitric oxide in cardiovascular disease. Mol Aspects Med 26: 33-65.
68. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al,. (2003). American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941-2948.
69. Niegowska J, Niegowska M, JasiÅski B, (2005). Telmisartan in monotherapy of essential hypertension in young men-time of drug administration and 24-hours blood pressure and heart rate. Pol Arch Med Wewn 114: 868-873.
70. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, et al,. (2006). Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99: 1426-1432.
71. Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, et al,. (1995). Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 76: 536-543.
72. Ono Y, Nakaya Y, Bando S, Soeki T, Ito S, Sata M, (2009). Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int Heart J 50: 73-83.
73. Onody A, Zvara A, Hackler L Jr, Vígh L, Ferdinandy P, Puskás LG, (2003). Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett 536: 35-40.
74. Palee S, Chattipakorn S, Phrommintikul A, Chattipakorn N, (2011). PPARΥ activator, rosiglitazone: is it beneficial or harmful to the cardiovascular system? World J Cardiol 3: 144-152.
75. Palmer RM, Ashton DS, Moncada S, (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666.
76. Patel RR, (2009). Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Cardiol Rev 17: 132-135.
77. Pechánová O, Bernátová I, Babál P, Martínez MC, Kyselá S, Stvrtina S, et al,. (2004). Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 22: 1551-1559.
78. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM, (2005). Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810-1816.
79. Puddu P, Puddu GM, Zaca F, Muscari A, (2000). Endothelial dysfunction in hypertension. Acta Cardiol 55: 221-232.
80. Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE, (2008). Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153: 636-645.
81. Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC, (2006). Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 6: 231-242.
82. Ruilope LM, (2011). Telmisartan for the management of patients at high cardiovascular risk. Curr Med Res Opin 27: 1673-1682.
83. Rush JW, Denniss SG, Graham DA, (2005). Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol 30: 442-474.
84. Saltiel AR, Olefsky JM, (1996). Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669.
85. Schupp M, Janke J, Clasen R, Unger T, Kintscher U, (2004). Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057.
86. Takahashi S, Mendelsohn ME, (2003). Synergistic activation of endothelial nitric oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem 278: 30821-30827.
87. Tontonoz P, Hu E, Spiegelman BM, (1995). Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5: 571-576.
88. Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, et al,. (2011). Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-Υ-dependent activity. Biochem Biophys Res Commun 410: 508-513.
89. Vaziri ND, Wang XQ, (1999). cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 34: 1237-1241.
90. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al,. (2004). Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 95: e45-e55.
91. Wenzel P, Schulz E, Oelze M, Müller J, Schuhmacher S, Alhamdani MS, et al,. (2008). AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 45: 619-626.
92. Wong WT, Tian XY, Xu A, Yu J, Lau CW, Hoo RL, et al,. (2011). Adiponectin is required for PPARΥ-mediated improvement of endothelial function in diabetic mice. Cell Metab 14: 104-115.
93. Wyatt AW, Steinert JR, Mann GE, (2004). Modulation of the L-arginine/nitric oxide signalling pathway in vascular endothelial cells. Biochem Soc Symp 71: 143-156.
94. Xiao Z, Wang T, Qin H, Huang C, Feng Y, Xia Y, (2011). Endoplasmic reticulum Ca2+ release modulates endothelial nitric-oxide synthase via extracellular signal-regulated kinase (ERK) 1/2-mediated serine 635 phosphorylation. J Biol Chem 286: 20100-20108.
95. Yamagishi S, Takeuchi M, (2005). Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64: 476-478.
96. Yang P, Li Y, Li JJ, Qin L, Li XY, (2010). Up-regulating PPAR-Υ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: the possible antiatherogenic and antithrombotic effects of atorvastatin. Int J Cardiol 139: 213-217.
97. Yu J, Zhang Z, Li Z, Feng X, He L, Liu S, et al,. (2010). Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 38: 86-94.
98. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW, Yu J, et al,. (2011). Telmisartan inhibits vasoconstriction via PPARΥ dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 90: 122-129.
99. Zheng J, Bird IM, Melsaether AN, Magness RR, (1999). Activation of the mitogen-activated protein kinase cascade is necessary but not sufficient for basic fibroblast growth factor- and epidermal growth factor-stimulated expression of endothelial nitric oxide synthase in ovine fetoplacental artery endothelial cells. Endocrinology 140: 1399-1407.
100. Zoechling A, Liebner F, Jungbauer A, (2011). Red wine: a source of potent ligands for peroxisome proliferator-activated receptor Υ. Food Funct 2: 28-38.